 |
| May
8, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- Biogen: Update on FDA Priority Review of
LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous
Injection as a Starting Dose for Early
Alzheimer’s Disease More
- Butterfly Network: Appoints Caroll H.
Neubauer to Board of Directors More
- Harbour BioMed: U.S. FDA IND Clearance for
HBM7004 for the Treatment of Advanced Solid
Tumors More
- Pyxis Oncology: Appoints Nelson Azoulay
as Chief Business Officer More
- Repertoire Immune Medicines: FDA Fast Track
Designation for Its Investigational Immune
Medicine, RPTR-1-201 More
- Reprieve Cardiovascular: Publication of
FASTR Pilot Trial Results in JACC: Heart
Failure
More
- Solid Biosciences: Doses First Participant
in Phase 3 IMPACT DUCHENNE Clinical Trial
Evaluating SGT-003 in Duchenne Muscular
Dystrophy More
|
|
 |
Charles
River CFO
Keeping It Steady During a
Company-Defining Moment |
|
Learn More
→ |
|
|
- Beam Therapeutics: First Quarter 2026
Financial Results and Recent Business Updates
More
- Bedford Med-Device Firm to Close
Seattle-Area Plant, Move Work Out of US More*
- Bluejay Diagnostics: First Quarter 2026
Corporate Update
More
- CAMP4: First Quarter 2026 Financial Results
and Corporate Highlights More
- Cue Biopharma: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Ginkgo Bioworks: First Quarter 2026
Financial Results, Completes Divestiture of
Biosecurity and Continues to Scale Autonomous
Lab More
- Inogen: First Quarter 2026 Financial Results
More
- KALA BIO: Reverse Stock Split More
- LSN: Hot Investor Mandates (Updated 5/5) More
- MBX Biosciences: First Quarter 2026
Financial Results and Corporate Highlights More
- More on Banyan BioInnovations Putting Down
Roots With $100M, Icon Partnership More
- More on Blackstone Putting $250M Into
Anagram to Tackle Cystic Fibrosis Complication
More*
More
- More on EnGene’s Shares Crashing on Updated
Pivotal Bladder Cancer Data More*
- More on Entrada Stock Falling on Duchenne
Data More*
More*
More
More
- More on Sarepta Tumbling as Its Gene Therapy
Sales Decline Further More
- Myomo: First Quarter 2026 Financial and
Operating Results
More
- Odyssey Therapeutics: Pricing of Upsized
Initial Public Offering More More
More*
- Organogenesis: First Quarter 2026 Financial
Results More
- Prime Medicine: First Quarter 2026 Financial
Results and Business Updates More
- Roche Spends Up to $1.05B to Buy Boston
AI Company More*
More More
- Stoke Therapeutics: First Quarter 2026
Financial Results and Business Updates More
- Tectonic Therapeutic: First Quarter 2026
Financial Results and Recent Business
Highlights
More
- 2026 Q1 Job Market Report: Job Postings
Picked Up as Quarter Progressed
More
- Verastem Oncology: First Quarter 2026
Financial Results and Recent Business Updates
More
- Voyager: First Quarter 2026 Financial and
Operating Results More
- Werewolf Therapeutics: First Quarter 2026
Financial Results and Recent Corporate Updates
More
- Xilio Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
|
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- BioPharmGuy News: Imaging Amateurs,
Hantavirus Scare, Angry Birds, £15k Lunch
More
- 400: Seaport’s IPO Adventure, Obesity Pill
Battles, and Makary’s Troubles Podcast
- Oncodesign Services Extends
Collaboration With GIP ARRONAX to Strengthen
Astatine-211 Supply for Targeted Alpha
Radiotherapy. More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- From Seed to Series C: What
Investors Look for Beyond the Science More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
- Pfizer’s Strategy Chief Andrew Baum Steps
Down; Helus Pharma Swaps Out CEO After Two
Months More*
- Telling Your Science Story to
Investors More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
